Klarithrin

Clarithromycin, the active ingredient in Klarithrin, is a macrolide antibiotic presented as a tablet for oral use. It treats bacterial infections such as community‑acquired respiratory tract infections, skin and soft‑tissue infections, sinusitis, otitis media, and is used in combination therapy for Helicobacter pylori eradication. GNH USA supplies Klarithrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic that acts on a broad range of bacterial pathogens causing infections in the respiratory, skin and gastrointestinal systems. Community‑acquired pneumonia: resolves infection and reduces respiratory symptoms. Skin and soft‑tissue infections: eradicates causative bacteria and promotes healing. Helicobacter pylori eradication therapy: used in combination regimens to achieve bacterial clearance. Sinusitis: alleviates infection and associated congestion. Otitis media: treats middle‑ear bacterial infection effectively.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal pain: cramping or discomfort. - Altered taste: metallic or bitter sensation. - Headache: mild to moderate intensity. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - QT prolongation: risk of serious cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, rash, swelling. - Clostridioides difficile‑associated colitis: severe diarrhea. - Stevens‑Johnson syndrome: skin blistering and detachment. - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances.

Before initiating Klarithrin therapy, consider the following precautions. - Assess renal and hepatic function: adjust therapy based on organ status. - Avoid in patients with known macrolide hypersensitivity: risk of severe allergic reaction. - Monitor ECG in patients at risk for QT prolongation: prevent arrhythmias. - Use cautiously with concomitant CYP3A4 substrates: potential drug‑interaction. - Adjust dose in severe hepatic impairment: reduce exposure. - Store at room temperature: keep in original pack, protect from moisture and light.

Clarithromycin may interact with several medications, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole): increased clarithromycin levels and toxicity. - QT‑prolonging agents (e.g., sotalol, quinidine): heightened risk of arrhythmia. - Statins metabolized by CYP3A4 (e.g., simvastatin): risk of myopathy. - Warfarin: potentiation of anticoagulant effect, increased INR.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced clarithromycin efficacy. - Oral contraceptives: possible decreased contraceptive effectiveness. - Theophylline: increased plasma concentrations, risk of toxicity. - Digoxin: potential rise in serum levels, monitor renal function.